Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide Chronotherapy for High Grade Glioma
NCT02781792Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2016
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temozolomide in glioma, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Feasibility of Patient Treatment Compliance and Duration of Response. Started Aug 2016; status: completed.
02
Drugs
temozolomide
03
Conditions
gliomaglioblastoma multiforme (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT02781792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781792.